Dennis Fiegen;Takeshi Kono;Silke Hobbie;Andreas Schnapp;Yayoi Sato;Annette Schuler-Metz;Sandra Handschuh;Matthias Hoffmann
发明人:
Dennis Fiegen,Sandra Handschuh,Silke Hobbie,Matthias Hoffmann,Takeshi Kono,Yayoi Sato,Andreas Schnapp,Annette Schuler-Metz
申请号：
US13057330
公开号：
US08604049B2
申请日:
2009.07.23
申请国别(地区):
US
年份:
2013
代理人:
摘要：
The invention relates to novel substituted naphthyridines of formula 1 as well as pharmacologically acceptable salts, diastereomers, enantiomers, racemates, hydrates, or solvates thereof. In formula 1, R1 can represent a group A selected from among the group comprising —O—R3, —NR3R4, —CR3R4R5, -(ethyne)-R3, —S—R3, —SO—R3, and SO2—R3, or R1 represents a group B selected from among the group comprising: —C6-10-aryl； —a five-membered to ten-membered, monocyclic or bicyclic heteroaryl containing 1 to 3 heteroatoms independently selected from among the group comprising N, O, and S, wherein said heteroaryl is linked to the structure according to formula 1 via a C atom or an N atom； —a three-membered to ten-membered, monocyclic or bicyclic, saturated or partially saturated heterocycle containing 1 to 3 heteroatoms independently selected from among the group comprising N, O, and S, wherein said heterocycle is linked to the structure according to formula 1 via a C atom or an N atom； and —a 5-membered to 11-membered spiro group which can optionally contain 1, 2, or 3 heteroatoms independently selected from among the group comprising N, O, and S, wherein said spiro group is linked to the structure according to formula 1 via a C atom or an N atom, wherein said group B can be optionally substituted as described in claims 1, and R3, R4, R5, R6, and m can have the meanings indicated in claim 1. The invention also relates to pharmaceutical compositions containing said compounds.
